Header graphic for print
Dangerous Drugs & Medical Devices News & Commentary on Prescription Drug & Medical Device Lawsuits

2007 – Study shows rate for Proscar side effects higher than warning label

Posted in Propecia / Proscar

In 2007, five years before Proscar and Propecia warning labels were required to be updated by the FDA to include information on sexual side effects, an important paper was published in Clinical Therapeutics by MJ Naslund titled “A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate.”.

This study reviewed “the natural history of enlarged prostate and the data supporting management of this condition with alpha-blocker and 5ARI therapy, either as monotherapy or combination therapy, for symptomatic relief and a reduction in long-term disease progression.”  To be clear, the active chemical in Propecia and Proscar is finasteride, a drug in the 5alpha-reductase inhibitor class.

Evaluating a number of studies published in MedLine from 1996-2006, the team found that finasteride was effective in reducing prostate size and improving other benign prostatic hyperplasia symptoms.  It was also found that “sexual dysfunction [was] the most frequently reported adverse effect” and affected between 1-8% of patients.  Warning labels for the above-described drugs suggested no rate above 4%.

Because of this discrepancy, a number of Proscar lawsuits and Propecia lawsuits have been filed.  If you or a loved one used Proscar or Propecia and suffered sexual side effects, you may be entitled to significant financial compensation.  For a free, no-obligation case consultation, contact our team of Proscar lawyers and Propecia lawyers at the information provided below.  We have the experience, resources, and skills required to win the justice you deserve.

(855) 452 – 5529